WO2023217184A3 - Substituted pyridine or pyrimidine derivative, pharmaceutical composition thereof, preparation method, and use - Google Patents

Substituted pyridine or pyrimidine derivative, pharmaceutical composition thereof, preparation method, and use Download PDF

Info

Publication number
WO2023217184A3
WO2023217184A3 PCT/CN2023/093248 CN2023093248W WO2023217184A3 WO 2023217184 A3 WO2023217184 A3 WO 2023217184A3 CN 2023093248 W CN2023093248 W CN 2023093248W WO 2023217184 A3 WO2023217184 A3 WO 2023217184A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted pyridine
pyrimidine derivative
preparation
pharmaceutical composition
drug
Prior art date
Application number
PCT/CN2023/093248
Other languages
French (fr)
Chinese (zh)
Other versions
WO2023217184A2 (en
Inventor
栾林波
姚元山
陈永凯
王朝东
Original Assignee
上海美悦生物科技发展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海美悦生物科技发展有限公司 filed Critical 上海美悦生物科技发展有限公司
Publication of WO2023217184A2 publication Critical patent/WO2023217184A2/en
Publication of WO2023217184A3 publication Critical patent/WO2023217184A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure relates to a substituted pyridine or pyrimidine derivative and a use thereof. Specifically, provided are a substituted pyridine or pyrimidine compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which can be used for preparing a drug, and particularly for preparing a drug for preventing and/or treating a p38 MAPK/MK2 pathway-mediated disease or disorder. Each group in formula (I) is as defined in the description.
PCT/CN2023/093248 2022-05-12 2023-05-10 Substituted pyridine or pyrimidine derivative, pharmaceutical composition thereof, preparation method, and use WO2023217184A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202210533240.2 2022-05-12
CN202210533240 2022-05-12
CN202211139876.5 2022-09-19
CN202211139876 2022-09-19

Publications (2)

Publication Number Publication Date
WO2023217184A2 WO2023217184A2 (en) 2023-11-16
WO2023217184A3 true WO2023217184A3 (en) 2023-12-28

Family

ID=88729709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/093248 WO2023217184A2 (en) 2022-05-12 2023-05-10 Substituted pyridine or pyrimidine derivative, pharmaceutical composition thereof, preparation method, and use

Country Status (2)

Country Link
CN (1) CN117800948A (en)
WO (1) WO2023217184A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130143906A1 (en) * 2011-12-06 2013-06-06 Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl-pyrimidinyl compounds
CN103391718A (en) * 2010-12-06 2013-11-13 汇合生命科学股份有限公司 Substituted pyridinone-pyridinyl compounds
WO2022212489A1 (en) * 2021-03-31 2022-10-06 Xinthera, Inc. Mk2 inhibitors and uses thereof
CN116396274A (en) * 2022-01-06 2023-07-07 深圳信立泰药业股份有限公司 Substituted bipyridone compound and preparation method and application thereof
CN116444493A (en) * 2022-01-14 2023-07-18 上海翰森生物医药科技有限公司 Derivative containing double parallel rings, preparation method and application thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103391718A (en) * 2010-12-06 2013-11-13 汇合生命科学股份有限公司 Substituted pyridinone-pyridinyl compounds
US20130143906A1 (en) * 2011-12-06 2013-06-06 Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl-pyrimidinyl compounds
WO2022212489A1 (en) * 2021-03-31 2022-10-06 Xinthera, Inc. Mk2 inhibitors and uses thereof
CN116396274A (en) * 2022-01-06 2023-07-07 深圳信立泰药业股份有限公司 Substituted bipyridone compound and preparation method and application thereof
CN116444493A (en) * 2022-01-14 2023-07-18 上海翰森生物医药科技有限公司 Derivative containing double parallel rings, preparation method and application thereof

Also Published As

Publication number Publication date
CN117800948A (en) 2024-04-02
WO2023217184A2 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
WO2021086833A8 (en) Small molecule inhibitors of kras g12c mutant
NO327709B1 (en) 2'-substituted 1,1'-biphenyl-2-carbonamides, their use in the preparation of a drug as well as pharmaceutical preparations containing them
BR0307351A (en) Compound, pharmaceutical composition, method for treating a p38 kinase activity-mediated or cytokine-mediated condition or condition produced by p38 kinase activity, use of a compound, and process for preparing a compound
CA2495685A1 (en) Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists
MX347544B (en) Polycyclic lpa1 antagonist and uses thereof.
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
NO20071577L (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory diseases
JP2013532729A5 (en)
NO20076425L (en) Methods of Treating Drug-Resistant Cancer
WO2009073148A3 (en) Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide)
BRPI0911476A2 (en) pyridazinone glycokinase activating compounds, pharmaceutical composition, use of the compounds, method for treating a disease and / or metabolic disorder and process for preparing the compounds
WO2007041666B1 (en) Preparation of rosuvastatin
US20070249676A1 (en) Cyanoguanidine prodrugs
BRPI0408727A (en) compound, process for preparing same, pharmaceutical composition, method for treating a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by p38 kinase activity, and use of a compound
JP2017533964A5 (en)
BRPI0511524A (en) compound or a pharmaceutically acceptable salt thereof, prodrug, method for producing an antibacterial effect on a warm-blooded animal, compound or a pharmaceutically acceptable salt thereof, or an in vivo hydrolysable ester thereof, use of a compound or a pharmaceutically acceptable salt thereof, or an in vivo hydrolysable ester thereof, a pharmaceutical composition, and process for the preparation of a compound or a pharmaceutically acceptable salt thereof, or an in vivo hydrolysable ester thereof
NO20022591L (en) Finely form of (S) -2-ethoxy-3- [4- (2- {4- methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
JP2019527724A5 (en)
BR0308108A (en) Compounds; process for the preparation of compound; pharmaceutical composition comprising the same, use of compounds and method of treatment and prophylaxis of diseases and obesity
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
MX2020013847A (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof.
CA2494601A1 (en) N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
CA3155875A1 (en) Sulfo-substituted biaryl compounds or salts thereof and preparation method and use thereof
WO2023217184A3 (en) Substituted pyridine or pyrimidine derivative, pharmaceutical composition thereof, preparation method, and use
BRPI0511526A (en) compound, prodrug, method for producing an antibacterial effect on a warm-blooded animal, use of a compound, pharmaceutical composition, and process for preparing a compound

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23802953

Country of ref document: EP

Kind code of ref document: A2